Most researchers trying to source CJC-1295 in Eike soon discover that local retail options are essentially nonexistent. What this means for Eike researchers is that physical proximity is irrelevant compared to your ability to evaluate vendor quality — and those quality checks are available to every researcher. A legitimate CJC-1295 supplier's COA needs to show HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all corresponding to the vial you receive. Use this guide to evaluate CJC-1295 vendors rigorously — the standards covered in this guide work regardless of your location.
Understanding CJC-1295 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Eike researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Buying CJC-1295: Quality Markers to Look For
The most effective path to quality CJC-1295 is starting with community forums — peptide forums aggregate real purchasing experience that are more accurate than commercial vendor claims. Endotoxin testing in the COA is non-negotiable for any injectable research use — endotoxins from bacterial cell wall components can trigger serious immune reactions even at minute levels. For Eike researchers evaluating unfamiliar vendors: a small initial order to verify quality before scaling up your order is standard practice in the community. Hold lyophilised CJC-1295 at minus 20 degrees Celsius until ready to use; reconstitute only the quantity required for your immediate research and return unused portion to the freezer.
Order CJC-1295 — ships to Eike
COA-verified · International tracking · Research grade
CJC-1295 operates beyond the scope of approved drug regulation — researchers should understand that the risk characterisation for this compound is based on preclinical evidence rather than regulated clinical data. Reconstitute CJC-1295 with bacteriostatic water at the concentration suited to your research design; a standard 5mg in 2mL gives a 2.5mg/mL solution — or 25mcg per insulin syringe unit. Bacterial endotoxin contamination is the primary safety concern specific to research peptides — verify endotoxin testing is present in the lot-matched certificate before any injectable research application. For any individual considering CJC-1295 outside a formal research context: speak with a healthcare professional — this compound is not approved for human use and its safety characterisation does not match that of regulated drugs.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
